TP53 and neoplasm: Taking the many approaches discussed into account, the resultant increase in complication-free cure is likely to achieve improvements by as much as 10–25% and more for many tumor sites, e.g., using PRIMA-1 and APR-246 [35] for the problematic TP53-mutant tumors.